Phase Ⅲ Trial of Rilvegostomig in HER2-positive Gastric Cancer Initiated by AstraZeneca
AstraZeneca is conducting Phase Ⅲ trial to evaluate rilvegostomig combined with fluoropyrimidine and T-DXd in HER2-positive gastric cancer.
Asset / Drug
Drug and asset intelligence for fluoropyrimidine with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.